Jared Moskowitz
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
1 flagRep. Moskowitz bought $1K-$15K in AbbVie (ABBV) on Jan 15, 2025 — 26 days before S.494 (National Plan for Epilepsy Act) was introduced, a bill that could boost epilepsy-related drug demand.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) [ST] | $1K-$15K | $171.35 | — | — | Jan 15, 2025 |
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) [ST] | $1K-$15K | $171.35 | — | — | Jan 15, 2025 |
| BUY | $GS | Goldman Sachs Group, Inc. (GS) [ST] | $1K-$15K | $605.92 | — | — | Jan 15, 2025 |
| BUY | $GS | Goldman Sachs Group, Inc. (GS) [ST] | $1K-$15K | $605.92 | — | — | Jan 15, 2025 |
| BUY | $GS | Goldman Sachs Group, Inc. (GS) [ST] | $1K-$15K | $605.92 | — | — | Jan 15, 2025 |
| BUY | $MCK | McKesson Corporation Common Stock (MCK) [ST] | $1K-$15K | $583.45 | — | — | Jan 15, 2025 |
| BUY | $MCK | McKesson Corporation Common Stock (MCK) [ST] | $1K-$15K | $583.45 | — | — | Jan 15, 2025 |
| BUY | $SYK | Stryker Corporation Common Stock (SYK) [ST] | $1K-$15K | — | — | — | Jan 15, 2025 |
| BUY | $SYK | Stryker Corporation Common Stock (SYK) [ST] | $1K-$15K | — | — | — | Jan 15, 2025 |
| SELL | $ABT | Abbott Laboratories Common Stock (ABT) [ST] | $1K-$15K | $111.10 | $93.86 | -15.5% | Jan 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Fair Access to Banking Act
HR987, the Fair Access to Banking Act, is an early-stage bill with 92 cosponsors that has been referred to committee with no hearings or markups. With no funding authorization and manageable incremental compliance costs, market impact is minimal. Financial sector stocks show no price movement attributable to this bill. JPMorgan ($312.83) has gained 6.35% in 30 days and Bank of America ($53.27) has gained 9.25% in 30 days on broader sector strength, not this legislation.
Chief Risk Officer Enforcement and Accountability Act
HR1910 (Chief Risk Officer Enforcement and Accountability Act) is an early-stage bill that codifies existing Fed CRO regulations for large banks, with the structural change of extending requirements to privately held large banks. Publicly traded mega-banks (JPM, BAC, WFC, C, MS, GS) already comply — no new costs. The bill creates incremental demand for compliance consulting and software vendors like ACN, IBM, and ORCL but is in early committee stage with low passage probability.
ABC Safe Drug Act
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
National Plan for Epilepsy Act
S.494, the National Plan for Epilepsy Act, is an early-stage coordination bill with zero authorized spending. It creates an advisory council and mandates federal research coordination for epilepsy but appropriates no funds. Market impact is negligible — no direct revenue driver for any public company.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
Providing Veterans Essential Medications Act
HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.
Climate Change Financial Risk Act of 2025
The Climate Change Financial Risk Act of 2025 (HR2823) would impose mandatory biennial climate risk capital evaluations and resolution plans on large U.S. banks. This creates direct compliance costs for JPMorgan, Bank of America, Citigroup, Goldman Sachs, and Morgan Stanley, while generating demand for consulting and IT services from Accenture and IBM. The bill is in early legislative stages with a companion bill in the Senate, but has low near-term passage probability given partisan dynamics and its early committee referral status.
Medicare for All Act
Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.
EPIC Act of 2025
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
Access to Pediatric Technologies Act of 2025
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
Other Filings by Jared Moskowitz
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.